Q-plasia OncoReader

The precision oncology company 4D Path has committed to partnering with the U.K.-based University of Leeds at least until 2027. The two entities are already collaborators, having worked together on three completed breast cancer clinical trials. In particular, researchers at the University of Leeds have used 4D Path’s Q-plasia OncoReader Breast software to analyze data from more than 1,000 patients over the past three years. 4D Path says its technology can help in various levels in clinical trials starting from patient recruitment for therapy eligibility, which can be challenging for rare mutations, to designing trials for therapy benefit and potentially suggesting drug target screens. The company's technology supports biomarker profiling and stratification from hematoxylin and eosin (H&E) whole slide biopsy and resection images. The platform can help researchers identify the cancer subtype, grade, presence of human epidermal growth factor receptor 2 (HER2) and horm…